Skip to main content
SpringerLink
Log in

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Treatment options for nonmuscle invasive urothelial carcinoma of the bladder (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG) instillations are currently limited and often total resection of the bladder is the only therapeutic option for these patients. Thus, novel treatment options that are safe and effective are needed to avoid the substantial treatment morbidity, impact on the quality of life and the significant surgical risk associated with radical cystectomies. Besides intravesical cytotoxic therapies, immune checkpoint inhibitors, cytokines or cancer vaccines, different approaches of intravesical application of adenoviruses are being evaluated in BCG-unresponsive NMIBC. Recently, intravesical nonreplicating adenovirus vector-based gene therapy with nadofaragene firadenovec, which induces intravesical interferon expression, was approved for the treatment of BCG-unresponsive NMIBC by the US Food and Drug Administration after a recently published phase III trial. In this short review, different adenoviruses that are currently being investigated in BCG-unresponsive NMIBC are discussed and the therapeutic potential of nadofaragene firadenovec is highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  2. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75–94.

    Article  PubMed  Google Scholar 

  3. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–95.

    Article  PubMed  Google Scholar 

  4. Ripoll J, Ramos M, Montaño J, Pons J, Ameijide A, Franch P. Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca cancer registry associated to survival. BMC Cancer. 2021;21(1):676.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Nykopp TK, Batista da Costa J, Mannas M, Black PC. Current clinical trials in non-muscle invasive bladder cancer. Curr Urol Rep. 2018;19(12):101.

    Article  PubMed  Google Scholar 

  6. Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 world health organization grading classification systems in non-muscle-invasive bladder cancer: a European association of urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur Urol. 2017;72(5):801–13.

    Article  PubMed  Google Scholar 

  7. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol. 2013;189(3):834–9.

    Article  CAS  PubMed  Google Scholar 

  8. Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A, et al. Oncological outcomes of sequential Intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3(4):293–303.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kamat AM, Bellmunt J, Choueiri TK, Nam K, De Santis M, Dreicer R, et al. KEYNOTE-057: phase 2 study of pembrolizumab for patients (pts) with bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol. 2016;34(15):TPS4576.

    Article  Google Scholar 

  10. Black PC, Catherine T, Lerner SP, McConkey DJ, Lucia MS, Woods M, et al. S1605: phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer. J Clin Oncol. 2018;36(6):TPS527.

    Article  Google Scholar 

  11. Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, et al. Phase 1 trial of ALT-801, an interleukin-2/T cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011;17(24):7765–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor—armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12(1):305–13.

    Article  CAS  PubMed  Google Scholar 

  13. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2391–7.

    Article  CAS  PubMed  Google Scholar 

  14. Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36(10):440–7.

    Article  CAS  PubMed  Google Scholar 

  15. Papageorgiou A, Dinney CPN, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007;6(6):872–9.

    Article  CAS  PubMed  Google Scholar 

  16. Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, et al. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol. 2019;37(10):2041–9.

    Article  CAS  PubMed  Google Scholar 

  17. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E, Finnbladder Group. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study—FinnBladder III long-term results. J Urol. 2002;168(3):981–5.

    Article  CAS  PubMed  Google Scholar 

  18. Shepherd AR, Shepherd E, Brook NR. Intravesical bacillus Calmette-Guérin with interferon-alpha versus intravesical bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev. 2017;3(3):CD12112.

    PubMed  Google Scholar 

  19. Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, et al. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther. 2001;8(10):788–95.

    Article  CAS  PubMed  Google Scholar 

  20. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004;10(3):525–32.

    Article  CAS  PubMed  Google Scholar 

  21. Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CNP. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study. Cancer Gene Ther. 2014;21(3):91–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 2002;8(4):1258–70.

    CAS  PubMed  Google Scholar 

  23. Zhang X, Dong L, Chapman E, Benedict WF. Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Ther. 2008;15(12):817–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dinney CPN, Fisher MB, Navai N, O’Donnell MA, Cutler D, Abraham A, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190(3):850–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, et al. Intravesical rAd-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol. 2017;35(30):3410–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. U.S. Food and Drug Administration. FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer. 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-high-risk-non-muscle-invasive-bladder-cancer. Accessed 23 Mar 2023.

  27. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107–17.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria

    Dominik A. Barth &  Martin Pichler MD

  2. Translational Oncology, University Hospital of Augsburg, Augsburg, Germany

    Martin Pichler MD

Authors
  1. Dominik A. Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Pichler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Pichler MD.

Ethics declarations

Conflict of interest

D.A. Barth and M. Pichler declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barth, D.A., Pichler, M. Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer. memo 16, 189–192 (2023). https://doi.org/10.1007/s12254-023-00899-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-023-00899-w

Keywords

Search

Navigation